{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:01:44Z","timestamp":1791352904170,"version":"4.3.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Given that the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) is widely utilized in IBS-related clinical research but lacks an officially approved Chinese version (IBS-SSS-C), which has impeded its application in Chinese research contexts. This study aims to translate and cross-culturally adapt the IBS-SSS into a Chinese version, and validate its key properties, thereby developing a reliable and officially recognized tool for assessing IBS severity among the Chinese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We obtained translation permission for the IBS-SSS from the Rome Foundation, and translated and cross-culturally adapted it into a Chinese version according to the official guideline. Validation was performed as clinical trials assessing responsiveness to change (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f95), test\u2013retest reliability (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f35) and the floor-ceiling effects (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f95) of IBS-SSS-C. We assessed the IBS-SSS-C score\u2019s responsiveness to change using adequate relief (AR) as an anchor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Through forward and backward translation, and cross-cultural adaption, the IBS-SSS-C was developed and approved for use by the Rome Foundation. A significance difference in the absolute change of the IBS-SSS-C total score before and after treatment was found in the AR responder and non-responder groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001). This trend also emerged for the items abdominal pain severity (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.032), abdominal pain frequency (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001), and bowel habit satisfaction (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.036). There was good test\u2013retest reliability (\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f0.72) for the IBS-SSS-C total score, and a moderate to good correlation (\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f0.41\u20130.81) for each of its items. No floor or ceiling effect was found in either IBS-SSS-C or any of its item.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that the IBS-SSS-C appears to be a reliable and appropriate instrument for IBS outcome assessment in the Chinese population; nevertheless, further validation in larger-scale, multi-center studies is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1779402","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:40:46Z","timestamp":1778132446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Translation, cross-cultural adaptation and validation of the Chinese version of irritable bowel syndrome severity scoring system"],"prefix":"10.3389","volume":"13","author":[{"given":"Qian","family":"Li","sequence":"first","affiliation":[{"name":"State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]},{"name":"Chinese Medicine Syndrome Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]},{"name":"The Second Clinical College of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hao","family":"Mo","sequence":"additional","affiliation":[{"name":"The Second Clinical College of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qi","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]},{"name":"The Second Clinical College of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Clinical College of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jia","family":"Ni","sequence":"additional","affiliation":[{"name":"The Second Clinical College of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]},{"name":"Guangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Hui","family":"He","sequence":"additional","affiliation":[{"name":"Big Data Research Center of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Xiong","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Cai","family":"Fang","sequence":"additional","affiliation":[{"name":"Departement of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bo","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]},{"name":"Chinese Medicine Syndrome Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1053\/gast.2002.37095","article-title":"AGA technical review on irritable bowel syndrome","volume":"123","author":"Drossman","year":"2002","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5056\/jnm16214","article-title":"What is new in Rome IV","volume":"23","author":"Schmulson","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1365-2036.2010.04376.x","article-title":"Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact","volume":"32","author":"Zhao","year":"2010","journal-title":"Aliment Pharm Ther"},{"key":"ref5","first-page":"969","article-title":"A meta-analysis of the prevalence and risk factors of irritable bowel syndrome in Chinese community","volume":"53","author":"Zhang","year":"2014","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018","volume":"156","author":"Peery","year":"2019","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.26355\/eurrev_201904_17580","article-title":"Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis","volume":"23","author":"Flacco","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"10450","DOI":"10.3748\/wjg.v22.i47.10450","article-title":"Economic burden of irritable bowel syndrome in China","volume":"22","author":"Zhang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/gutjnl-2017-315136","article-title":"Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome","volume":"68","author":"Zhou","year":"2019","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1136\/gutjnl-2021-325821","article-title":"Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian health care knowledge Centre (KCE trials Programme) and the Rome foundation research institute","volume":"71","author":"Carbone","year":"2022","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/gutjnl-2018-317805","article-title":"Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial","volume":"68","author":"Everitt","year":"2019","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1572-0241.2003.07158.x","article-title":"Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics","volume":"98","author":"Bijkerk","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/gutjnl-2021-325214","article-title":"Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis","volume":"71","author":"Black","year":"2022","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.14309\/ajg.0000000000001395","article-title":"Peppermint oil treatment for irritable bowel syndrome: a randomized placebo-controlled trial","volume":"116","author":"Nee","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/apt.16934","article-title":"Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome","volume":"55","author":"L\u00f6vdahl","year":"2022","journal-title":"Aliment Pharm Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1055\/s-0033-1335260","article-title":"Validation of the IBS-SSS","volume":"51","author":"Betz","year":"2013","journal-title":"Z Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4321\/S1130-01082011001200002","article-title":"Translation, cultural adaptation and validation of a Spanish version of the irritable bowel syndrome severity score","volume":"103","author":"Almansa","year":"2011","journal-title":"Rev Esp Enferm Dig"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00535-006-1799-9","article-title":"Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index","volume":"41","author":"Shinozaki","year":"2006","journal-title":"J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13063-018-2754-9","article-title":"Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial","volume":"19","author":"Li","year":"2018","journal-title":"Trials"},{"key":"ref21","author":"Li","year":"2020"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"694741","DOI":"10.3389\/fphar.2021.694741","article-title":"Chinese herbal medicine for irritable bowel syndrome: a Meta-analysis and trial sequential analysis of randomized controlled trials","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11655-019-3030-x","article-title":"Post-marketing re-evaluation of Tongxiening granules () in treatment of diarrhea-predominant irritable bowel syndrome: a multi-center, randomized, double-blind, double-dummy and positive control trial","volume":"25","author":"Tang","year":"2019","journal-title":"Chin J Integr Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"111889","DOI":"10.1016\/j.jep.2019.111889","article-title":"The effect of Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial","volume":"238","author":"Shih","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ctim.2018.07.002","article-title":"Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?-a randomized controlled trial","volume":"40","author":"Wang","year":"2018","journal-title":"Complement Ther Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3109\/00365521.2013.825314","article-title":"Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial","volume":"48","author":"Begtrup","year":"2013","journal-title":"Scand J Gastroentero"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1046\/j.1365-2036.2003.01709.x","article-title":"Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome","volume":"18","author":"Corazziari","year":"2003","journal-title":"Aliment Pharm Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF01593882","article-title":"Individual-patient monitoring in clinical practice: are available health status surveys adequate?","volume":"4","author":"McHorney","year":"1995","journal-title":"Qual Life Res"},{"key":"ref29","volume-title":"IBM SPSS Statistics for Windows, Version 26.0","year":"2019"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"A797","DOI":"10.1177\/030006059802600203","article-title":"Adequate relief as an endpoint in clinical trials in irritable bowel syndrome","volume":"114","author":"Mangel","year":"1998","journal-title":"Gastroenterology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.gastro.2019.09.024","article-title":"Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial","volume":"158","author":"Cox","year":"2020","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/ecco-jcc\/jjaa241","article-title":"Hypnotherapy for irritable bowel syndrome-type symptoms in patients with quiescent inflammatory bowel disease: a randomized, controlled trial","volume":"15","author":"Hoekman","year":"2021","journal-title":"Controlled Trial J Crohns Colitis"},{"key":"ref34","author":"Zeng","year":"2020"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1779402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:40:48Z","timestamp":1778132448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1779402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1779402"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1779402","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"1779402"}}